ActiveSite Pharmaceuticals utilizes proprietary lead discovery technology to discover new small molecule drug candidates for human diseases with unmet medical need. Our initial efforts are focused on developing novel, innovative treatments for the major vision-threatening complication of diabetes, diabetic macular edema, and the genetic disease hereditary angioedema, by targeting the vascular protease plasma kallikrein.
